Despite a high cash burn, the significant 55% annual revenue growth of IDEAYA Biosciences is encouraging. The company's limited cash burn relative to market capitalisation suggests it should be able to fuel growth with minor dilution or borrowing. Cash burn thus shouldn't be a major concern.
$IDEAYA生物科学(IDYA.US)$IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, Her2-, BRCA1/2 mutant Breast Cancer
Netflix Upgraded to Buy From Sell at CFRA CFRA analyst Kenneth Leon double upgraded$奈飞(NFLX.US)$to Buy from Sell with a price target of $310, up from $225. The analyst believes it "will be difficult for competitors to catch" Netflix, noting it is one of the few profitable streaming providers with global scale. Capital One Starts Ideaya Biosciences at Overweight With $29 Price Target Capital One analyst Zegbeh Jallah initiated...
Gainers: •$Kezar Life Sciences(KZR.US)$+92% (announces positive top line results from the MISSION Phase 2 trial) •$Sutro Biopharma(STRO.US)$+24.5% (Sutro Biopharma and Astellas to collaborate to advance novel immunostimulatory antibody-drug conjugates) •$Ceragon(CRNT.US)$+17.7% (AVNW to acquire all shares of CRNT that it does not already own for $2.80/sh) •$携程网(TCOM.US)$+15.6% (In reaction to earnings/guidance) •$Apyx Medical(APYX.US)$+8% (anno...
IDEAYA生物科学股票讨论区
NEWS!
Another run soon?
starting to look good from a rookie persoe tive. Thanks in advance.
Did you get in
Thanks to peeps pushing me to be better.
PT $24 by analysis
专栏US Top Rating Updates on 12/30: NFLX, IDYA, GNRC, AMTI and More
CFRA analyst Kenneth Leon double upgraded $奈飞(NFLX.US)$ to Buy from Sell with a price target of $310, up from $225. The analyst believes it "will be difficult for competitors to catch" Netflix, noting it is one of the few profitable streaming providers with global scale.
Capital One Starts Ideaya Biosciences at Overweight With $29 Price Target
Capital One analyst Zegbeh Jallah initiated...
专栏Today's Pre-Market Stock Movers: BMY, ADBE, MSTR, AZN and More
Select biotech/pharma names showing strength following ESMO:
$Clovis Oncology(CLVS.US)$ +11.3%, $Cardiff Oncology(CRDF.US)$ +9%, $Immatics(IMTX.US)$ +8.3%, $IDEAYA生物科学(IDYA.US)$ +8%, $Lyra Therapeutics(LYRA.US)$ +5.7%, $POINT Biopharma(PNT.US)$ +5.7%, $Edgewise Therapeutics(EWTX.US)$ +4.7%, $Concert Pharmaceuticals(CNCE.US)$ +3.6%, $Deciphera Pharmaceuticals(DCPH.US)$ +3.2%, $Veracyte(VCYT.US)$ +2.6%, $SpringWorks Therapeutics(SWTX.US)$ +2.3%,...
专栏Today's Pre-Market Stock Movers: DWAC, BBBY, ILMN, DBX and More
In reaction to earnings/guidance:
• $联电(UMC.US)$ +0.8% (August revs)
Other news:
• $ChannelAdvisor(ECOM.US)$ +54.4% (to be acquired for $23.10 per share)
• $IVERIC bio(ISEE.US)$ +42.3% (topline data from Zimura GATHER2 phase 3 clinical trialingeographic atrophy)
• $Monte Rosa Therapeutics(GLUE.US)$ +10% (receives FDA clearance of Investigational New Drug Application for MRT-2359)
• $IDEAYA生物科学(IDYA.US)$ +4.9% (re...
专栏Today's pre-market stock movers: TCOM, OXY, SAVE, GS and more
• $Kezar Life Sciences(KZR.US)$ +92% (announces positive top line results from the MISSION Phase 2 trial)
• $Sutro Biopharma(STRO.US)$ +24.5% (Sutro Biopharma and Astellas to collaborate to advance novel immunostimulatory antibody-drug conjugates)
• $Ceragon(CRNT.US)$ +17.7% (AVNW to acquire all shares of CRNT that it does not already own for $2.80/sh)
• $携程网(TCOM.US)$ +15.6% (In reaction to earnings/guidance)
• $Apyx Medical(APYX.US)$ +8% (anno...
暂无评论